NCT06642909 - A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy | Biotech Hunter

Enrollment

135

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Primary Membranous Nephropathy

Interventions

DRUG

Zuberitamab 600mg

administered twice with a 2-week interval between each dose (i.e. D1, D15). One treatment cycle is 24 weeks

DRUG

Zuberitamab 1000mg

administered twice with a 2-week interval between each dose (i.e. D1, D15). One treatment cycle is 24 weeks

DRUG

cyclosporine

Initial dose of 3.5 mg/kg/d, oral administration, divided into two doses, taken 12 hours apart (Q12h)

Trial Locations (1)

Zhongshan Hospital Fudan University, Shanghai